COZAAR 100MG TABLET

Land: Malaysia

Sprache: Englisch

Quelle: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Wirkstoff:

LOSARTAN POTASSIUM

Verfügbar ab:

MERCK SHARP & DOHME (MALAYSIA) SDN BHD

INN (Internationale Bezeichnung):

LOSARTAN POTASSIUM

Einheiten im Paket:

30Tablet Tablets; 10 Tablet Tablets

Hergestellt von:

MERCK SHARP & DOHME LTD

Fachinformation

LOCAL PRODUCT CIRCULAR LPC -MK0954 -T-032018 -Malaysia
Tablets
COZAAR �
(losartan potassium)
I. THERAPEUTIC CLASS
COZAAR (losartan potassium), the first of a new class of agents for the treatment of
hypertension, is an angiotensin II receptor (type AT 1) antagonist. COZAAR also provides a
reduction in the combined risk of cardiovascular death, stroke, and myocardial infarction in
hypertensive patients with left ventricular hypertrophy and provides renal protection for type 2
diabetic patients with proteinuria.
II. CLINICAL PHARMACOLOGY
Mechanism of Action
Angiotensin II, a potent vasoconstrictor, is the primary active hormone of the renin- angiotensin
system, and a major determinant of the pa thophysiology of hypertension. Angiotensin II binds to
the AT 1
receptor found in many tissues (e.g., vascular smooth muscle, adrenal gland, kidneys,
and the heart) and elicits several important biological actions, including vasoconstriction and the
release of aldosterone. Angiotensin II also stimulates sm ooth muscle cell proliferation. A second
angiotensin II receptor has been identified as the AT 2
receptor subtype, but it plays no known
role in cardiovascular homeostasis.
Losartan is a potent, syn thetic, orally active compound. Based on binding and pharmacological
bioassays, it binds selectively to the AT 1
receptor.
In vitro and in vivo , both losartan and its
pharmacologically active carboxylic acid metabolite (E -3174) block all physiologically relevant
actions of angiotensin II, regardless of the source or route of synthesis. In contrast to some
peptide antagonists of angiotensin II, losartan has no agonist effects.
1